# Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

> **NCT00625014** · NA · COMPLETED · sponsor: **Leiden University Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Insulin Resistance
- Dyslipidemia

## Interventions

- **DRUG:** Haloperidol

## Key facts

- **NCT ID:** NCT00625014
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625014, "Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00625014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*